Summary

Global Neurological Disorder Diagnostics Market was valued at USD 9.45 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.45% through 2029. The Global Neurological Disorder Diagnostics Market encompasses a wide range of diagnostic tools, technologies, and services aimed at detecting and managing neurological conditions affecting the brain, spinal cord, and peripheral nerves. This market has been expanding steadily due to several factors, including an aging global population, rising prevalence of neurological disorders, advancements in diagnostic technologies, and increased awareness and emphasis on early diagnosis and intervention. Continued growth in this market is expected, driven by ongoing technological advancements, demographic shifts, and increased healthcare investments worldwide. The focus on personalized medicine, AI-driven diagnostics, and telemedicine solutions is set to shape the future of the industry, offering opportunities for market expansion and improved patient care outcomes.
Key Market Drivers
Increasing Prevalence of Neurological Disorders
As neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, and epilepsy become more prevalent globally, there is a heightened demand for early detection and accurate diagnosis. Early diagnosis allows healthcare providers to initiate timely interventions, optimize treatment strategies, and potentially improve patient outcomes. This demand fuels the adoption of advanced diagnostic technologies and drives market growth. The rising prevalence of neurological disorders places a substantial burden on healthcare systems worldwide. Governments and healthcare providers are increasingly investing in improving diagnostic capabilities to address the growing healthcare demands associated with these conditions. This investment drives innovation in diagnostic tools, techniques, and treatments, thereby expanding the market for neurological disorder diagnostics.
Neurological disorders are often age-related, and with global demographic shifts towards an aging population, the incidence of conditions like Alzheimer's disease and Parkinson's disease is expected to rise. Older adults are more susceptible to neurological conditions, necessitating enhanced diagnostic capabilities to manage these diseases effectively. The aging population demographic trend directly correlates with increased demand for neurology diagnostics. The prevalence of neurological disorders encourages continuous advancements in diagnostic technologies such as neuroimaging (MRI, CT, PET scans), genetic testing, and biomarker identification. These technological innovations enable more accurate and comprehensive diagnosis, aiding in early detection and personalized treatment planning. As healthcare providers strive to meet the diagnostic needs of a growing patient population, they increasingly invest in and adopt these advanced diagnostic tools. Neurological disorders not only affect individual patients but also have broader economic and social implications. The economic burden associated with untreated or misdiagnosed neurological conditions motivates healthcare systems to prioritize early detection and effective management through robust diagnostic capabilities. Moreover, societal awareness and advocacy for improved neurological healthcare drive policy reforms and funding initiatives, further supporting market growth in neurology diagnostics.
The increasing prevalence of neurological disorders drives the growth of the Global Neurological Disorder Diagnostics Market by stimulating demand for early detection, prompting healthcare investments in diagnostic technologies, leveraging demographic trends, fostering technological advancements, and addressing economic and social impacts. These factors collectively underscore the market's expansion and innovation in meeting the diagnostic challenges posed by neurological disorders globally.
Growing Emphasis on Early Diagnosis and Disease Management
Early diagnosis of neurological disorders enables healthcare providers to initiate timely and appropriate treatment strategies. Early intervention can slow disease progression, alleviate symptoms, and potentially improve patient outcomes, including quality of life. This clinical benefit encourages healthcare systems and providers to invest in advanced diagnostic technologies capable of detecting neurological conditions at their earliest stages.
There is an increasing recognition of the importance of personalized medicine in neurology, where treatment approaches are tailored to individual patient profiles based on early diagnostic insights. Advanced diagnostic tools, such as genetic testing, biomarker analysis, and neuroimaging techniques (MRI, CT, PET scans), provide detailed information about disease mechanisms and patient-specific characteristics. This shift towards personalized medicine drives the demand for precise and predictive diagnostics, thereby expanding the market for neurology diagnostics. Early diagnosis and proactive disease management in neurology can lead to significant cost savings for healthcare systems. By detecting neurological disorders early, healthcare providers can implement less invasive and more cost-effective treatments, avoid hospitalizations for preventable complications, and reduce long-term healthcare expenditures. This economic incentive motivates healthcare stakeholders to invest in advanced diagnostic technologies that facilitate early detection and management of neurological conditions.
Regulatory agencies and healthcare policymakers increasingly emphasize the importance of early diagnosis and disease management in improving patient outcomes and healthcare efficiency. Supportive regulatory frameworks facilitate the development, approval, and adoption of innovative neurology diagnostics. Clear regulatory pathways for new diagnostic technologies encourage investment in R&D and commercialization, fostering market growth and innovation in neurology diagnostics. Patient empowerment and engagement are driving the adoption of patient-centric care models in neurology. Patients and caregivers are increasingly proactive in seeking early diagnosis and participating in disease management decisions. This trend amplifies the demand for accessible, accurate, and patient-friendly diagnostic tools that facilitate informed decision-making and enhance patient care experiences. Advances in diagnostic technologies, including AI-driven algorithms, digital health solutions, and telemedicine platforms, support early diagnosis and remote monitoring of neurological disorders. These technologies enable healthcare providers to reach underserved populations, facilitate timely consultations, and improve diagnostic accuracy through data-driven insights. The integration of innovative technologies into neurology diagnostics expands market opportunities and enhances healthcare delivery efficiency globally.
The growing emphasis on early diagnosis and disease management drives the growth of the Global Neurological Disorder Diagnostics Market by promoting improved patient outcomes, supporting personalized medicine approaches, reducing healthcare costs, fostering a supportive regulatory environment, empowering patients, and leveraging technological advancements. These factors collectively contribute to market expansion and innovation in neurology diagnostics, meeting the evolving healthcare needs of patients and healthcare providers worldwide.
Technological Advancements in Diagnostics
Advanced neuroimaging techniques, such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and functional MRI (fMRI), have revolutionized the ability to visualize and characterize neurological conditions. These technologies provide detailed anatomical, functional, and metabolic information about the brain and nervous system, enabling clinicians to make more accurate diagnoses and treatment decisions. The integration of advanced imaging modalities with AI-driven algorithms further enhances diagnostic accuracy by automating image analysis, detecting subtle abnormalities, and predicting disease progression.
Biomarkers, including genetic markers, proteins, and metabolic markers, play a crucial role in diagnosing and monitoring neurological disorders. Technological advancements in biomarker discovery, such as next-generation sequencing (NGS), proteomics, and metabolomics, enable the identification of specific biomarkers associated with neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These biomarkers facilitate early detection, personalized treatment strategies, and monitoring of treatment efficacy, driving the demand for specialized diagnostic tests and enhancing market growth. AI and ML algorithms are transforming neurology diagnostics by analyzing complex datasets, predicting disease outcomes, and optimizing treatment protocols. In neuroimaging, AI algorithms can detect subtle changes in brain structure or function that may indicate neurological disorders, improving diagnostic accuracy and efficiency. AI-powered decision support systems assist clinicians in interpreting diagnostic results, reducing diagnostic errors, and enhancing patient care outcomes. The integration of AI and ML technologies into diagnostic workflows accelerates data-driven insights and innovation in neurology diagnostics, driving market expansion. The adoption of telemedicine platforms and digital health solutions has facilitated remote access to neurological diagnostics and specialist consultations. Telemedicine enables patients in remote or underserved areas to receive timely diagnostic evaluations, reducing geographical barriers to healthcare access. Digital health tools, including mobile applications, wearable sensors, and remote monitoring devices, provide continuous real-time data on patients' neurological status, supporting early detection of symptoms and disease progression monitoring. These technological innovations enhance patient engagement, improve healthcare delivery efficiency, and expand market opportunities for neurology diagnostics globally. Miniaturization of diagnostic devices and the development of point-of-care testing (POCT) technologies enable rapid and on-site diagnosis of neurological disorders. Portable imaging devices, handheld diagnostic tools, and biosensors facilitate immediate diagnostic assessments in clinical settings, emergency departments, and remote locations. These advancements reduce turnaround times for diagnostic results, enhance healthcare provider decision-making capabilities, and improve patient outcomes by enabling timely interventions.
Technological advancements in diagnostics drive the growth of the Global Neurological Disorder Diagnostics Market by enhancing diagnostic accuracy, enabling biomarker discovery, integrating AI and ML capabilities, facilitating telemedicine and digital health solutions, and advancing miniaturization and POCT technologies. These innovations support early diagnosis, personalized treatment approaches, and improved patient care outcomes, positioning neurology diagnostics at the forefront of healthcare innovation globally.
Key Market Challenges
Complexity and Heterogeneity of Neurological Disorders
Neurological disorders encompass a wide spectrum of conditions with diverse etiologies, symptoms, and progression patterns. This complexity poses significant challenges in accurate diagnosis and treatment planning. Many neurological disorders lack specific biomarkers or diagnostic tests, leading to delays in diagnosis, misdiagnosis, and variability in patient outcomes. Healthcare providers face difficulties in standardizing diagnostic protocols and interpreting diagnostic results across different patient populations. Addressing these challenges requires robust research efforts, collaboration among multidisciplinary teams, and advancements in personalized medicine approaches tailored to individual patient profiles.
High Development Costs and Regulatory Hurdles
Developing and commercializing diagnostic technologies for neurological disorders involve substantial research and development (R&D) costs, stringent regulatory requirements, and lengthy approval processes. Innovators must navigate complex regulatory landscapes across different regions, adhering to safety, efficacy, and quality standards set by regulatory authorities like the FDA (Food and Drug Administration) in the United States and the EMA (European Medicines Agency) in Europe. These regulatory hurdles increase time-to-market and financial burdens, particularly for novel diagnostic tests and technologies requiring clinical validation. As a result, some innovative solutions may face delays in market entry or limited accessibility, hindering market growth and innovation adoption.
Limited Access to Specialized Healthcare Services
Disparities in healthcare access and resources contribute to challenges in delivering specialized neurological diagnostics, particularly in rural or underserved regions globally. Access to neurologists, specialized diagnostic facilities (e.g., neuroimaging centers), and advanced diagnostic technologies varies widely, affecting timely diagnosis and management of neurological disorders. Furthermore, socioeconomic factors, insurance coverage limitations, and healthcare infrastructure gaps impact patient access to diagnostic tests and follow-up care. Addressing these access barriers requires healthcare system investments in telemedicine, training of healthcare professionals, and public health initiatives to improve awareness, early detection, and equitable distribution of neurology diagnostics.
Key Market Trends
Advancements in Biomarker Development and Molecular Diagnostics
As technology improves, there's a growing emphasis on biomarkers—indicators of biological processes or conditions within the body. In neurological disorders, biomarkers play a crucial role in early detection, disease monitoring, and treatment response assessment. Advances in molecular diagnostics, such as next-generation sequencing (NGS) and liquid biopsy techniques, enable more precise identification of biomarkers associated with neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These developments enhance diagnostic accuracy, facilitate personalized medicine approaches, and drive market growth by providing clinicians with actionable insights for patient care.
Integration of Artificial Intelligence (AI) and Machine Learning (ML)
AI and ML are revolutionizing healthcare by enhancing diagnostic capabilities, particularly in interpreting complex data from neuroimaging, genetic testing, and clinical assessments. AI algorithms can analyze large datasets to identify patterns, predict disease progression, and optimize treatment strategies. In neurology diagnostics, AI-powered tools aid in image interpretation (e.g., MRI, CT scans), genetic variant analysis, and patient risk assessment. This integration improves diagnostic efficiency, reduces diagnostic errors, and supports clinicians in making informed decisions, thereby fostering market expansion as healthcare providers adopt these technologies to enhance patient outcomes.
Telemedicine and Remote Monitoring Solutions
The adoption of telemedicine and remote monitoring solutions has accelerated, driven by advancements in digital health technologies and the need for accessible neurological care, especially in remote or underserved areas. Telemedicine enables neurologists to remotely diagnose and monitor patients, conduct virtual consultations, and facilitate continuous disease management. Remote monitoring devices, such as wearable sensors and mobile health apps, provide real-time data on patients' neurological status, allowing for early detection of changes and timely intervention. These solutions improve patient access to specialized care, enhance clinical workflow efficiency, and contribute to market growth as healthcare systems embrace telehealth as a sustainable model for neurology diagnostics and management.
Segmental Insights
Disease Indication Insights
Based on the category of Disease Indication, the Genetic Neurological Disorders segment emerged as the dominant in the global market for Neurological Disorder Diagnostics in 2023. Genetic neurological disorders, such as Huntington's disease, Duchenne muscular dystrophy, and certain types of epilepsy, have a notable prevalence worldwide. The incidence rates of these disorders contribute to a consistent demand for diagnostic tools and services. There have been significant advancements in genetic testing technologies, such as next-generation sequencing (NGS) and molecular diagnostics, which have enabled more accurate and comprehensive diagnosis of genetic neurological disorders. These technologies allow for early detection, personalized treatment strategies, and better disease management.
Increased awareness among healthcare professionals and the general population about genetic neurological disorders has led to proactive screening and diagnostic initiatives. Screening programs aim to identify at-risk individuals, facilitating early intervention and genetic counseling. The development of targeted therapies and treatments for specific genetic neurological disorders has further emphasized the need for accurate and early diagnosis. Diagnostic tests are crucial for identifying eligible patients for these therapies and monitoring treatment efficacy. Pharmaceutical companies, diagnostic laboratories, and research institutions are investing heavily in the development of new diagnostic technologies and treatments for genetic neurological disorders. This investment stimulates market growth and innovation in diagnostic approaches. These factors collectively contribute to the growth of this segment.
Regional Insights
North America emerged as the dominant in the global Neurological Disorder Diagnostics market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, possesses highly developed healthcare infrastructure. This includes advanced hospitals, diagnostic laboratories, and research facilities equipped with state-of-the-art diagnostic technologies. The availability of such infrastructure supports accurate and timely diagnosis of neurological disorders. The region is at the forefront of technological innovation in healthcare, including neurology diagnostics. Advanced imaging techniques such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography), PET (Positron Emission Tomography), and EEG (Electroencephalography) are widely available and utilized for diagnosing various neurological conditions. North America has a high prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. The aging population, coupled with lifestyle factors, contributes to the increasing incidence of these disorders, driving the demand for diagnostic tests and services.
Government initiatives, policies, and funding support research and development in neurology diagnostics. Regulatory bodies such as the FDA (Food and Drug Administration) in the United States ensure stringent standards for the approval and commercialization of diagnostic technologies, fostering innovation and market growth. North America is home to many leading healthcare providers, academic institutions, and research organizations specializing in neurology and neuroimaging. These institutions collaborate with industry partners to develop and commercialize advanced diagnostic technologies.
Key Market Players
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Esaote SPA
• NeuroLogica Corp.
• Masimo Corp
• Neusoft Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Abbott Laboratories Inc
Report Scope:
In this report, the Global Neurological Disorder Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Neurological Disorder Diagnostics Market, By Product:
o Imaging
o In Vitro Diagnostics
• Neurological Disorder Diagnostics Market, By Disease Indication:
o Genetic Neurological Disorders
o Immunological Neurological Disorders
o Paraneoplastic Syndrome
o Paraproteinemic Neuropathies
• Neurological Disorder Diagnostics Market, By End User:
o Hospitals and Specialty Clinics
o Diagnostic Centres
o Ambulatory Care Centers
• Neurological Disorder Diagnostics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neurological Disorder Diagnostics Market.
Available Customizations:
Global Neurological Disorder Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Neurological Disorder Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Imaging, In Vitro Diagnostics)
5.2.2. By Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies)
5.2.3. By End User (Hospitals and Specialty Clinics, Diagnostic Centres, Ambulatory Care Centers)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map
6. North America Neurological Disorder Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Disease Indication
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Neurological Disorder Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Disease Indication
6.3.1.2.3. By End User
6.3.2. Canada Neurological Disorder Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Disease Indication
6.3.2.2.3. By End User
6.3.3. Mexico Neurological Disorder Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Disease Indication
6.3.3.2.3. By End User
7. Europe Neurological Disorder Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Disease Indication
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Neurological Disorder Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By End User
7.3.2. United Kingdom Neurological Disorder Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By End User
7.3.3. Italy Neurological Disorder Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By End User
7.3.4. France Neurological Disorder Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Disease Indication
7.3.4.2.3. By End User
7.3.5. Spain Neurological Disorder Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Disease Indication
7.3.5.2.3. By End User
8. Asia-Pacific Neurological Disorder Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Disease Indication
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Neurological Disorder Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By End User
8.3.2. India Neurological Disorder Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By End User
8.3.3. Japan Neurological Disorder Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By End User
8.3.4. South Korea Neurological Disorder Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Disease Indication
8.3.4.2.3. By End User
8.3.5. Australia Neurological Disorder Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Disease Indication
8.3.5.2.3. By End User
9. South America Neurological Disorder Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Disease Indication
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Neurological Disorder Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By End User
9.3.2. Argentina Neurological Disorder Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By End User
9.3.3. Colombia Neurological Disorder Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By End User
10. Middle East and Africa Neurological Disorder Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Disease Indication
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Neurological Disorder Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Neurological Disorder Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By End User
10.3.3. UAE Neurological Disorder Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Neurological Disorder Diagnostics Market: SWOT Analysis
14. Competitive Landscape
14.1. Siemens Healthineers AG
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Financials (If Listed)
14.1.4. Recent Developments
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Koninklijke Philips N.V.
14.3. Esaote SPA
14.4. NeuroLogica Corp.
14.5. Masimo Corp
14.6. Neusoft Corporation
14.7. CANON MEDICAL SYSTEMS CORPORATION
14.8. Abbott Laboratories Inc.
15. Strategic Recommendations
16. About Us & Disclaimer